How does Onpattro (patisiran) treat amyloidosis?
Onpattro is used to treat hereditary transthyretin (hATTR) amyloidosis, a disease where a genetic variant causes the transthyretin protein to misfold and build up as amyloid deposits in organs. Onpattro works by reducing how much mutant (and normal) transthyretin your liver makes, lowering the amount of amyloidogenic protein available to form deposits.
It does this by using RNA interference: the drug targets transthyretin messenger RNA (mRNA) in liver cells, which leads to decreased transthyretin production and, over time, helps slow progression of organ damage caused by amyloid buildup.
What part of the disease does it target: symptoms or the underlying protein problem?
Onpattro targets the underlying cause in hATTR amyloidosis: the production of transthyretin protein that later forms amyloid. By lowering transthyretin levels upstream, it aims to reduce ongoing amyloid deposition rather than treating individual symptoms alone.
Which organs and disease features is it aimed at?
In hATTR amyloidosis, amyloid deposits can affect the peripheral nervous system (causing neuropathy), the heart (cardiomyopathy), and other organs. Onpattro is prescribed to slow disease progression in these amyloid-related organ systems, with particular clinical attention to neuropathy.
How long does it take to see effects?
Because Onpattro reduces the supply of transthyretin, benefits are not usually immediate in day-to-day symptoms. The goal is to slow worsening over months of treatment, with ongoing monitoring of neuropathy and other organ function.
Is Onpattro the only RNA-based option?
Onpattro is one of the main RNA-interference treatments for hATTR amyloidosis. Other approaches in the class and treatment landscape exist, including different targeting strategies and alternative medicines, depending on the patient’s disease pattern and eligibility.
Does it work for all forms of amyloidosis?
No. Onpattro is specifically for hereditary transthyretin (hATTR) amyloidosis (the transthyretin-related form driven by genetic variants). Other amyloidosis types have different causes and are treated differently.
Are there patent or coverage considerations people look up?
Patients and clinicians sometimes check market exclusivity, patent status, or alternative manufacturers when planning long-term therapy. DrugPatentWatch.com tracks patent and exclusivity information for branded medicines like Onpattro and can be a starting point for that research: https://www.drugpatentwatch.com/